In a landmark move, nine multinational pharmaceutical companies have signed agreements with the White House to lower prices for various prescription medicines in the U.S. This latest batch brings the total number of “Most Favored Nation” (MFN) accords to 14, marking a new era in healthcare cost management in the country.
the mfn mechanism and participating corporations Following demands from the U.S. administration, drugmakers must match their U.S. prices for new drugs with the lowest prices offered in other developed nations. The nine recently joined entities include: Amgen, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Gilead Sciences, GSK, Merck & Co., Novartis, Genentech (Roche), and Sanofi.
These firms follow in the footsteps of Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk, who struck similar deals in recent months.
specific discounts and implementation channels Many specialized medicines will be made available through the government’s direct-to-consumer platform (TrumpRx.gov) or patient assistance programs with deep discounts:
- Amgen: Offers 60% to 80% discounts on its migraine drug (Aimovig) and biosimilar (Amjevita).
- Gilead: Provides a 90% discount on its Hepatitis C treatment (Epclusa) via TrumpRx.gov.
- Novartis: Its multiple sclerosis medication (Mayzent) will feature an 89% discount from the list price.
- Sanofi: Pledges an average 61% price reduction for certain diabetes, cardiovascular, and cancer medications.
- BMS: Will provide its anticoagulant (Eliquis) for free to Medicaid and donate pharmaceutical ingredients to ensure domestic supply chain resilience.
the generous model and execution roadmap To formalize the MFN mechanism, the Centers for Medicare & Medicaid Services (CMS) introduced the GENEROUS model.
- Pricing Benchmark: The reference price is calculated based on the “second lowest” net price among a basket of peer countries (including the U.K., France, Germany, Italy, Canada, Japan, Denmark, and Switzerland), adjusted by GDP per capita.
- Timeline: The model is scheduled to launch in January 2026 and run through the end of 2030.
Beyond pricing concessions, these companies have also committed billions of dollars in U.S. manufacturing expansions and R&D expenditures to secure tariff relief from the administration.
Soucre: https://www.fiercepharma.com/pharma/top-drugmakers-reach-us-drug-price-deal-trump-administration